Korro Bio, Inc. today announced a $91.5 million Series A financing to advance its novel platform for precise, single-base, RNA editing to modulate protein function for therapeutic applications. This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies.


Korro Bio is creating transformative therapeutics for patients by selectively editing messenger RNA to recode specific codons to deliver a beneficial change in protein sequence, structure, and function.

Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics

Description

Company Information

Funding Insights

Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information